logo-loader
Quadrise Fuels International PLC

Investor Update: Quadrise to work with Merlin Energy on upstream heavy oil projects

Headlines from the Proactive UK newsroom.

Quadrise (LON:QFI) has signed another agreement for its alternative fuel MSAR. E&P consultant Merlin Energy and Quadrise will work together to find applications for MSAR in heavy oil environments.

i3 Energy (LON:I3E)  says its drilling rig is ready to move to the Liberator field. The semi-submersible rig will drill a pilot well to optimise the location of a first production well and test the Serenity prospect in a 94-day drilling programme.

ReNeuron (LON:RENE) has received a £250,000 grant to work on its exosome-based drug delivery technology platform with the stem cell research unit at the University of Cardiff.

Rail passengers are bracing for another meaty fare rise ahead of today’s RPI inflation numbers for July. That is the benchmark used to set rail fares and economists forecast a 2.8% rise this time.

Train operator FirstGroup (LON:FGP) meanwhile has won the franchise for the West Coast main line in a partnership with Italian from Trenitalia. The new Partnership will operate from 8 December 2019.

Sports Direct’s (LON:SPD) auditor Grant Thornton is stepping down. After reviewing its list of clients, the accountant said it had decided not to seek re-appointment with Mike Ashley’s group.

Quick facts: Quadrise Fuels International PLC

Price: 3.2 GBX

Market: LSE
Market Cap: £31.86 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Quadrise Fuels International PLC named herein, including the promotion by the Company of Quadrise Fuels International PLC in any Content on the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Faron Pharmaceuticals makes 'groundbreaking discovery' in its MATINS trial

Faron Pharmaceuticals Oy (LON:FARN) (FIRSTNORTH:FARON) CEO Dr Markku Jalkanen speaks to Proactive London's Andrew Scott after updating on its phase I/II MATINS trial of Clevegen. He says it's been encouraging to discover that Clevegen can ‘down’ regulate a range of checkpoints that affect the...

2 days, 12 hours ago

2 min read